| Recruiting | Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma NCT06124976 | University of British Columbia | Phase 2 / Phase 3 |
| Withdrawn | Efficacy and Safety of UGN-101 in Recurrent Patients NCT04006691 | UroGen Pharma Ltd. | Phase 3 |
| Completed | Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patient NCT01191892 | Cardiff University | Phase 2 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relaps NCT01031875 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Loc NCT01089088 | Cardiff University | Phase 2 |
| Completed | Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Ca NCT00792025 | Institut Curie | Phase 2 |
| Unknown | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the NCT00757614 | Cancer Research UK | — |
| Completed | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally NCT01090466 | Cardiff University | Phase 1 / Phase 2 |
| Completed | Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastat NCT00623064 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 1 |
| Completed | Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium NCT00397488 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Ur NCT01118039 | Hospital del Mar | Phase 2 |
| Completed | Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants NCT00900276 | Wake Forest University Health Sciences | — |
| Completed | Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium NCT00053209 | Eastern Cooperative Oncology Group | Phase 2 |
| Terminated | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium NCT00087295 | SWOG Cancer Research Network | Phase 2 |
| Completed | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pel NCT00066352 | University Health Network, Toronto | Phase 2 |
| Completed | S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the U NCT00066612 | SWOG Cancer Research Network | Phase 2 |
| Completed | S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Canc NCT00045630 | SWOG Cancer Research Network | Phase 2 |
| Completed | Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer NCT00028860 | Tulane University Health Sciences Center | Phase 2 |
| Terminated | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract NCT00022633 | SWOG Cancer Research Network | Phase 2 |
| Completed | Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radica NCT00080795 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer NCT00022191 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract NCT00014144 | SWOG Cancer Research Network | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Func NCT00005644 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium NCT00014274 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 / Phase 3 |
| Completed | SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract NCT00006351 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract NCT00006026 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | R115777 in Treating Patients With Advanced Bladder Cancer NCT00006376 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer NCT00004223 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Oxaliplatin in Treating Patients With Metastatic Bladder Cancer NCT00004203 | University of Chicago | Phase 2 |
| Unknown | Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Ca NCT00005958 | Amgen | Phase 2 |
| Completed | Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tr NCT00006111 | UNICANCER | Phase 2 |
| Completed | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With A NCT00003376 | Eastern Cooperative Oncology Group | Phase 3 |
| Completed | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium NCT00310011 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer NCT00003342 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer NCT00003175 | Medical Research Council | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer NCT00003105 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer NCT00003133 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract NCT00002914 | Eastern Cooperative Oncology Group | Phase 2 |